Navigation Links
Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
Date:1/13/2009

CALGARY, Jan. 13 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted its 31st U.S. Patent, # 7,476,382, entitled "Reovirus for the Treatment of Neoplasia." The patent includes claims to pharmaceutical compositions containing reovirus.

"This U.S. patent expands and strengthens our proprietary position for REOLYSIN(R)," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics. "The pharmaceutical composition claims cover the formulation being used in our ongoing clinical trials."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company's business and technologies, involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOL
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
(Date:1/14/2014)... 14, 2014 In recent years, growing ... methods in product development and promotion has led to ... mistrust, fueled by concerns about the insidious impact of ... of spectacular fines to the world’s biggest pharmas for ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Global ... developing innovative information technology solutions for patients, physicians, ... care stakeholders, announced today the signing of a ... Food and Drug Administration (FDA). This initiative ...
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... With the first observation of thermoelectric effects at ... transistors have a nanoscale cooling effect that reduces their ... William King and electrical and computer engineering professor Eric ... April 3 advance online edition of the journal ...
... conventional optical instruments, light cannot be focused to spot ... effects. An important approach to beat this diffraction ... an allusion to their radiofrequency counterparts. They have the ... nanometer-scale dimensions, which are orders of magnitude smaller than ...
... Diego have produced the first high resolution structure of a ... was published in a paper in this week,s early online ... of Sciences by a team of chemists headed by ... UCSD. The scientists said the ability to carry structural ...
Cached Biology Technology:Self-cooling observed in graphene electronics 2Transmission lines for nanofocusing of infrared light 2Transmission lines for nanofocusing of infrared light 3
(Date:4/24/2014)... New Rochelle, NY, April 24, 2014D-ribose is a ... nutritional supplement, and as a starting compound for ... of Escherichia coli to increase the ... step toward achieving more efficient industrial-scale production of ... in Industrial Biotechnology , a peer-reviewed journal ...
(Date:4/24/2014)... simple and cheap way of making a high-powered lens ... microscope. , Costing less than a cent, the lenses ... countries and remote areas. , The lens fabrication technique ... National University (ANU) Research School of Engineering, who collaborated ... Medical Research to find ways to transform the lentil-sized ...
(Date:4/24/2014)... Initial treatment for a brain infection caused by fungus could ... due to study by University of Liverpool scientists. , ... often fatal but are relatively neglected in medical research. ... Africa, Australasia and South East Asia and mainly affect people ... people a year. , The University research team has tested ...
Breaking Biology News(10 mins):Droplet lens 2Treatment for deadly yeast disease reduced to 3 days 2
... Reportlinker.com announces that a new market research report is ... Forecast to 2012 - http://www.reportlinker.com/p096440/Global-Biometric-Forecast-to-2012.html ... the fastest emerging markets for the past few years ... and the advent of new technologies that offered numerous ...
... and "Invasive Alien Species in the Caribbean Basin of Concern ... will be presented at a joint meeting between the Southeastern ... Caribbean Division of the American Phytopathological Society (APS). The ... San Juan, March 19-22, 2011, as hundreds of entomologists and ...
... To the surprisingly inventive uses for banana peels ... of house plants scientists have added purification of ... which concludes that minced banana peel performs better than ... journal Industrial & Engineering Chemistry Research . ...
Cached Biology News:Reportlinker Adds Global Biometric Forecast to 2012 2CSI and alien invaders in Puerto Rico 2
...
RABBIT ANTI PORCINE CARBOXYPEPTIDASE B...
LabFax: Immunochemistry...
... Maker, 1. Modular system for large ... up to six lab-cast or precast ... with 18- or 24-cm Immobiline DryStrip ... gel cassettes.Innovative design simplifies loading and ...
Biology Products: